Jenex Approved for Publication by Standard & Poor's

Tuesday October 30, 2007

BURLINGTON, ON, Oct. 30 /Business Wire/ - The Jenex Corporation (TSX Venture Exchange: JEN; Frankfurt: JNX; at Yahoo Finance, use (JEN.V) announced its company information will be available via S&P's Market Access Program, disseminated to users of S&P's Advisor Insight, an Internet-based research engine used by more than 100,000 investment advisors. The information includes all pertinent financial information.  It will also be available via S&P's Stock Guide database, distributed to virtually all major quote vendors. A full description will be published in the Daily News section of Standard Corporation Records, a securities manual for secondary trading in approximately 38 states under Blue Sky Laws.  

Jenex President Michael Jenkins commented: "We are immensely pleased we will be featured in S&P’s various publications. This is one of our planned steps to widely publicize Jenex’s expansion.”

About Jenex:  Jenex has a clinically proven non-invasive Medical Device that is approved for the Prevention of cold sore outbreaks. The interceptCS™ Cold Sore Prevention System is approved in Canada and has received CE mark approval for European Union countries.  interceptCS™  is a new entry into the cold sore treatment market place which currently is being offered topicals and prescription drugs from companies such as but not limited to Glaxosmithkline (GSK:NYSE), Novartis (NYSE:NVS), and Zila Inc (NASDAQ:ZILA).  interceptCS™ has a superior claim to all other cold sore products that claim to speed relief after eruption. Jenex, on the other hand claims “Cold Sore Prevention.”

Also, Jenex markets Therapik®, a device that immediately relieves the pain & itch caused by the stings & bites of over 20,000 different species of insects. Therapik® is approved in Canada, Australia, and the United States, as well as having CE Mark approval in the European Union countries. Jenex's Thermal Therapy technology is patented in the U.S., Canada, Australia, & Europe.  Jenex has the potential to dominate two huge underdeveloped markets. See www.interceptCS.com and www.JenexCorp.com.

The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events.

Contact:

The Jenex Corporation, Michael Jenkins, 905-632-3830, jenex@jenexcorp.com

For S&P Media Relations:  Michael Privitera, 212-438-6679